Pregnancy and rheumatoid arthritis

Area of Science:

• Rheumatology
• Immunology
• Obstetrics

Background:

• Rheumatoid arthritis (RA) often shows remission during pregnancy, though a significant minority experience persistent or worsening disease.
• Postpartum relapse is common for patients who initially improve.
• The underlying mechanisms for pregnancy-induced RA remission are not fully understood but may involve hormonal and immunological shifts.

Purpose of the Study:

• To review the impact of pregnancy on rheumatoid arthritis disease activity.
• To discuss the safety and efficacy of various treatments for RA during pregnancy.
• To outline a rational approach to managing RA in pregnant patients.

Main Methods:

• Literature review of studies on rheumatoid arthritis in pregnancy.
• Analysis of current treatment guidelines for RA management during gestation.
• Summary of known risks and benefits of RA medications in pregnancy.

Main Results:

• Most pregnant women with RA experience an uncomplicated course with no increased maternal or fetal morbidity.
• Fertility is not generally affected in patients with RA.
• Safe medication options include sulfasalazine, hydroxychloroquine, paracetamol, and low-dose prednisone, while methotrexate and leflunomide are contraindicated.

Conclusions:

• While many RA patients improve during pregnancy, careful monitoring and management are essential.
• Treatment decisions must prioritize maternal and fetal safety, with specific drug contraindications and preferences noted.
• A strategic, individualized approach is crucial for managing rheumatoid arthritis throughout pregnancy and the postpartum period.